Berry Oncology

Berry Oncology is a Chinese commercial entity operating in the oncology genomics and precision medicine space. It is based in Fuzhou, China, and is associated with the Berry Genomics group, a Chinese life-sciences company known for next-generation sequencing (NGS) services. Berry Oncology focuses on the application of genomic technologies to cancer, including tumor genomic profiling, liquid biopsy, and related clinical testing services intended to support precision oncology decision-making. The company operates primarily in the Chinese market, where demand for tumor molecular diagnostics has grown alongside the broader adoption of targeted cancer therapies and immunotherapy. Its offerings are aimed at hospitals, oncology clinicians, pharmaceutical partners, and patients seeking molecular information about their tumors. As part of the Berry Genomics ecosystem, Berry Oncology can draw on sequencing infrastructure, bioinformatics capabilities, and clinical laboratory operations developed by its parent organization. Berry Oncology's positioning sits at the intersection of clinical diagnostics and cancer research services. It competes in a crowded Chinese precision-oncology testing market that includes both domestic and international players. Its brand identity is tied to the parent Berry Genomics name, which carries recognition in the Chinese genomics industry. Because public, independently verifiable information about Berry Oncology specifically is limited, this dossier relies on the entity's identification as a company in Fuzhou, China, and on well-established facts about its parent group. Details such as exact founding date, ownership structure, and product portfolio should be confirmed against the company's official communications.

Berry Oncology is a Chinese company based in Fuzhou, China. It operates within the broader Berry Genomics group, a Chinese life-sciences organization active in next-generation sequencing and genomic services. The parent group, Berry Genomics, was established in the 2010s and became one of China's better-known genomics companies, providing sequencing services for research, clinical, and reproductive health applications. Berry Oncology was created to focus the group's genomic capabilities on cancer. Its work centers on tumor molecular diagnostics, an area that expanded rapidly in China as targeted therapies and immuno-oncology drugs entered clinical practice. These treatments often require molecular testing to identify actionable mutations, and companies such as Berry Oncology provide the laboratory testing and interpretation services that support such decisions. The company's location in Fuzhou places it within Fujian province's growing biotechnology and healthcare sector. Berry Oncology's activities are tied to the parent group's sequencing platforms, laboratory network, and bioinformatics pipeline, which it leverages for oncology-specific assays. Publicly available, independently verifiable details about Berry Oncology's corporate history — such as exact incorporation dates, funding rounds, or leadership changes — are limited. The entity is documented as a company in Fuzhou, China, and its brand is closely associated with Berry Genomics. Further historical specifics should be sourced from official company disclosures.

Clinical oncology genomics and precision diagnostics provider within the Berry Genomics group.

Product categories. Tumor genomic profiling · Liquid biopsy testing · Next-generation sequencing (NGS) cancer panels · Precision oncology diagnostic services

1. 1Berry Oncology (China) - Wikidatawikidata.org
2. 2Berry Oncology official websiteberryoncology.com